scholarly journals Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India

PLoS ONE ◽  
2019 ◽  
Vol 14 (12) ◽  
pp. e0227009 ◽  
Author(s):  
Yamuna Devi Bakthavatchalam ◽  
Priyanka Babu ◽  
Elakkiya Munusamy ◽  
Hariharan Triplicane Dwarakanathan ◽  
Priscilla Rupali ◽  
...  
2020 ◽  
Vol 34 ◽  
pp. 205873842092571
Author(s):  
Chanmei Lv ◽  
Jiantao Lv ◽  
Yue Liu ◽  
Qifeng Liu ◽  
Dongna Zou

The infection of the bone marrow system caused by methicillin-resistant Staphylococcus aureus (MRSA) leads to a variety of common diseases which usually occur in children under the age of 12. Vancomycin (VCM) is the first-line therapy for MRSA-caused serious infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin and soft-tissue infection (e.g. necrotizing fasciitis) with a recommended dosage of 15–20 μg/mL. In this study, we first report a case of a child with MRSA-caused osteomyelitis who was successfully cured by VCM at a concentration of 4.86 μg/mL. VCM’s clinical daily dose of more than 4 g was of concern in light of recent evidence suggesting the increased risks of nephrotoxicity and red man syndrome when Cmin ⩾15 μg/mL and doses ⩾10 mg/kg in children. As far as we know, this is the first report on the lower dose of VCM in children with MRSA osteomyelitis.


2017 ◽  
Vol 364 (16) ◽  
Author(s):  
Hidemasa Nakaminami ◽  
Teruyo Ito ◽  
Xiao Han ◽  
Ayumu Ito ◽  
Miki Matsuo ◽  
...  

Author(s):  
José Givanildo Silva ◽  
Wydemberg José Araujo ◽  
Elma Lima Leite ◽  
Larissa Maranhão Dias ◽  
Priscylla Carvalho Vasconcelos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document